AbCellera Biologics Expected to Post Q2 Losses with $0.17 EPS
ByAinvest
Thursday, Jul 31, 2025 11:22 am ET1min read
ABCL--
The consensus EPS estimate has been revised 4.17% lower over the last 30 days, indicating a reassessment by analysts of the company's earnings prospects. This revision suggests that analysts are collectively becoming more cautious about ABCL's earnings potential [1].
The Zacks Earnings ESP (Expected Surprise Prediction) for ABCL is currently at +4.00%, indicating that analysts have recently become more bullish on the company's earnings prospects. This positive ESP, combined with a Zacks Rank of #3, suggests that ABCL is likely to beat the consensus EPS estimate [1].
Historically, ABCL has been able to beat consensus EPS estimates in three out of the last four quarters, with the most recent quarter reporting a surprise of +11.76% [1]. This track record of beating estimates may indicate that ABCL has the potential to deliver a positive earnings surprise in its upcoming report.
Investors should pay close attention to the upcoming earnings report and the accompanying earnings call to gauge the company's near-term prospects. While an earnings beat or miss may not be the sole factor influencing ABCL's stock price, a positive surprise could lead to a short-term increase in stock price. Conversely, a miss could result in a decrease in stock price [1].
References:
[1] https://www.nasdaq.com/articles/abcellera-biologics-inc-abcl-expected-beat-earnings-estimates-can-stock-move-higher
AbCellera Biologics Inc. (ABCL) is expected to report a year-over-year decline in earnings on lower revenues for Q2 2025. The Zacks Consensus Estimate forecasts a quarterly loss of $0.17 per share and revenues of $6.92 million, down 5.5% YoY. The consensus EPS estimate has been revised 4.17% lower over the last 30 days. Investors should look for the direction of estimate revisions and the Zacks Earnings ESP to gauge the potential for a positive or negative earnings surprise.
AbCellera Biologics Inc. (ABCL) is set to report its quarterly earnings for Q2 2025, with analysts expecting a year-over-year decline in earnings due to lower revenues. The Zacks Consensus Estimate forecasts a quarterly loss of $0.17 per share, representing a 30.8% year-over-year change. Revenues are expected to be $6.92 million, down 5.5% from the year-ago quarter [1].The consensus EPS estimate has been revised 4.17% lower over the last 30 days, indicating a reassessment by analysts of the company's earnings prospects. This revision suggests that analysts are collectively becoming more cautious about ABCL's earnings potential [1].
The Zacks Earnings ESP (Expected Surprise Prediction) for ABCL is currently at +4.00%, indicating that analysts have recently become more bullish on the company's earnings prospects. This positive ESP, combined with a Zacks Rank of #3, suggests that ABCL is likely to beat the consensus EPS estimate [1].
Historically, ABCL has been able to beat consensus EPS estimates in three out of the last four quarters, with the most recent quarter reporting a surprise of +11.76% [1]. This track record of beating estimates may indicate that ABCL has the potential to deliver a positive earnings surprise in its upcoming report.
Investors should pay close attention to the upcoming earnings report and the accompanying earnings call to gauge the company's near-term prospects. While an earnings beat or miss may not be the sole factor influencing ABCL's stock price, a positive surprise could lead to a short-term increase in stock price. Conversely, a miss could result in a decrease in stock price [1].
References:
[1] https://www.nasdaq.com/articles/abcellera-biologics-inc-abcl-expected-beat-earnings-estimates-can-stock-move-higher
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet